Shandong Aonai Biopharmaceutical Co., Ltd., a professional pet supplement manufacturer and pet supplement supplier based in Linyi City, Shandong Province, China, has been officially designated as a drafting workgroup unit of the group standard T/CAQI 345-2023 Requirements for Pet Treat Quality and Safety Management, issued by the China Association for Quality Inspection (CAQI) on October 25, 2023. This designation marks the company's active participation in setting the quality and safety benchmarks for China's pet treat industry ― a category of growing importance to pet owners worldwide.
Group standard T/CAQI 345-2023 establishes the requirements for the quality and safety management of pet treats, covering key aspects of production, quality control, and safety management throughout the pet treat supply chain. As pet treats ― including dental chews, training treats, and functional snacks ― have become an increasingly important part of daily pet care, standardized quality management has become essential to protect pet health and build consumer trust.
The standard was initiated and issued by the China Association for Quality Inspection (CAQI), a national professional organization dedicated to quality inspection, quality supervision, and the promotion of product quality standards across Chinese industries. By participating in the drafting workgroup, Shandong Aonai Biopharmaceutical contributed its practical experience in pet food production and quality management to the formulation of this important industry benchmark.
The scope of the standard spans the full quality management chain of pet treats: raw material acceptance criteria, production environment and process control, hygiene management, packaging and labeling requirements, finished product inspection, and recall and traceability mechanisms. These provisions respond directly to the quality concerns that pet owners raise most often ― ingredient safety, consistent manufacturing, and honest labeling. As pet treats such as dental chews, calming chews,and functional snacks continue to grow in popularity around the world, the standard provides a clear framework that helps both domestic producers and international buyers evaluate product quality on a common basis.
As a drafting workgroup unit, Shandong Aonai Biopharmaceutical participated in the development of the standard's technical requirements, drawing on:
Production expertise: years of hands-on experience in pet food and supplement manufacturing, with a full-chain quality control system covering raw material sourcing, production processing, and finished product inspection;
Safety management practice: an FSPCA PCQI-certified R&D team with internationally recognized food safety preventive control capabilities, bringing global best practices into the standard-setting process;
Market insight: deep understanding of consumer expectations for safe, high-quality pet treats and snacks, ensuring the standard reflects real-world quality demands.
For international buyers evaluating suppliers, a supplier's participation in national group standard drafting is a powerful quality signal:
Quality commitment: companies that help write the rules are held to the highest interpretation of them. Partners can expect products that meet or exceed the benchmark standards the company itself helped establish;
Regulatory alignment: the company's active engagement with China's quality standardization system ensures its products stay ahead of regulatory developments, reducing compliance risk for importers;
Verifiable credibility: standard drafting participation is documented, verifiable evidence of the company's technical depth and industry standing ― a strong complement to its international credentials, including the Dutch granted patent for the Dr.kalan compound probiotic and the EPO's positive examination of its collagen peptide technology.
The quality management framework of T/CAQI 345-2023 aligns closely with the company's product portfolio, which spans dog joint supplements, dog multivitamins, dental care products, and digestive & probiotic supplements under its Dr.kalanbrand. Whether through OEM/ODM, private label, or bulk supply programs, partners can access factory-direct pet supplement manufacturer services with the assurance that products are produced under a quality management framework the company helped define.
Shandong Aonai Biopharmaceutical Co., Ltd. is a science-driven pet health enterprise located in the Wenshui Industrial Park, Pingyi County, Linyi City, Shandong Province, China. The company integrates R&D, production, and sales, with a product portfolio spanning dog joint supplements, dog multivitamins, dental care products, and digestive & probiotic supplements under its Dr.kalan brand. As an experienced pet supplement manufacturer and pet supplement supplier, the company offers flexible OEM/ODM, private label, and custom formula services to brands and distributors worldwide. Its quality assurance system is backed by an FSPCA PCQI-certified R&D team, and the company holds multiple international invention patents and patent applications covering its Dr.kalan compound probiotics and gastric acid-resistant collagen peptides. Committed to "quality first, safety first, technology driven," Shandong Aonai is dedicated to delivering safe, scientific, and premium pet health products to pets and pet parents around the world.
As a drafting unit of T/CAQI 345-2023, Shandong Aonai Biopharmaceutical will continue to uphold the highest quality and safety standards in its own production and contribute to the ongoing improvement of China's pet treat industry
EN
